Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding-Reference-Cited by-同舟云学术

Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding

Published:2024-08-28 Issue: Volume: Page:
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Apolo Andrea B.,Michaels-Igbokwe Christine^ORCID,Simon Nicholas I.,Benjamin David J.,Farrar Mallory,Hepp Zsolt,Mucha Lisa,Heidenreich Sebastian,Cutts Katelyn,Krucien Nicolas,Ramachandran Natasha,Gore John L.

Funder

Seagen

Astellas Pharma Inc.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40271-024-00709-3.pdf

Reference49 articles.

1. National Cancer Institute. What is bladder cancer? 2023. https://www.cancer.gov/types/bladder#:~:text=Urothelial%20carcinoma%20(also%20called%20transitional,bladder%20cancers%20are%20urothelial%20carcinomas. Accessed 23 April 2024.

2. Hepp Z, Shah SN, Smoyer K, Vadagam P. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis. J Manag Care Spec Pharm. 2021;27(2):240–55.

3. National Cancer Institute: Surveillance Epidemiology and End Results Program. Cancer stat facts: bladder cancer. National Institutes of Health; 2023. https://seer.cancer.gov/statfacts/html/urinb.html Accessed 23 March 2023.

4. Smith AB, Jaeger B, Pinheiro LC, Edwards LJ, Tan HJ, Nielsen ME, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121(4):549–57.

5. Manasee S, Jacob D, Sam W, Zsolt H, Sonali S. Patient-reported symptoms and impacts of locally advanced or metastatic urothelial cancer (la/mUC) after chemotherapy followed by a PD-1/PD-L1 checkpoint inhibitor (CPI). J Clin Oncol. 2019;37(suppl 7):380.